期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER-2与乳腺癌的关系研究进展 被引量：4

暂未订购
导出
摘要 HER-2基因是一种原癌基因,其基因扩增及蛋白的过度表达与乳腺癌转移、治疗及预后密切相关。现在人们仍然在不断深入探索HER-2基因在乳腺癌发生过程中发挥的作用,并不断完善其临床检测和治疗方法。HER-2基因已成为乳腺癌中的研究热点。
作者 张康 昝自亮 张本斯
机构地区 大理学院临床医学院心胸外科 大理学院解剖教研室
出处 《现代医药卫生》 2012年第2期252-254,共3页 Journal of Modern Medicine & Health
关键词 HER-2基因 乳腺癌 靶向治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Slamon D J, Clark GM , Wong SG,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987,235 (4785) : 177 - 182.
  • 2Lohriseh C ,Piceart M. An overview of HER-2 [J]. Semin Oneol,2001,28 (Suppl 18) : 3-11.
  • 3Sahin AA.Biologie and clinical significance of HER-2/neu(eerbB-2)in breast eaneer[J].Adv Anat Pathol, 2000,7(3) : 158-166.
  • 4Jukkola A,Bloigu R, Soini Y,et al.CerbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease[J].Eur J Cancer ,2001, 37(3) : 347-354.
  • 5Brewer GJ.Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer[J].Curr Cancer Drug Targets, 2005,5(3) : 195- 202.
  • 6Ross JS,Fletcher JA.The HER-2/neu oncogene in breast cancer:prognostic factor predictive factor and target for therapy [J].Oncologist, 1998,3(4):237-252.
  • 7Bender LM,Nahta R.Her-2 cross talk and therapeutic resistance in breast cancer[J].Front Biosci, 2008,13 : 3906-3912.
  • 8Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER-2-over-expression metastatic breast cancer.Herceptin multinational investigator study group [J]. Semin Oncol, 1999,26(4Suppl 12) :71-77.
  • 9De Laurentiis M,Cancello G,Zinno L,et al.Targeting Her2 as a therapeutic strategy for breast cancer :a paradigmatic shift of drug development in oncology[J]. Ann Oncol, 2005(16suppl 4) : 7-13.
  • 10Ritter CA,Perez-Torres M ,Rinehart C ,et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network[J].Clin Cancer Res, 2007,13(16) : 4909-4919.

同被引文献29

  • 1李坚.Effects of polysomy 17 on HER-2 gene and protein expression and its clinicopathologic significance in breast cancer[J].China Medical Abstracts(Internal Medicine),2013,30(1):19-20. 被引量：1
  • 2Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity [J]. Nat Rev Clin Oncol, 2010,7(3):139-147.
  • 3I-lurvitz SA, Finn RS. What's positive about 'triple-negative' breast cancer[J]? Future Oncol, 2009,5(7) : 1015-1025.
  • 4Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy [ J ]. Expert Rev Mol Diagn, 2008,8 ( 4 ) : 417-434.
  • 5Albeck JG, Brugge JS. Uncovering a tumor suppressor for triplenegative breast cancers [ J ]. Cell, 2011,144 (5) : 638-640.
  • 6Hunter T. Tyrosine phosphorylation: thirty years and counting [J ]. Curr Opin Cell Biol, 2009,21 (2) : 140-146.
  • 7Rimawi MF, Shetty PB, Weiss HL, et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes [J]. Cancer, 2010,116(5) : 1234- 1242.
  • 8Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer [J]. Front Biosci, 2008,13:3906-3912.
  • 9Sun T, Aeeto N, Meerbrey KL, et al. Activation of multiple proto- oneogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase [J]. Cell, 2011,144 (5) : 703-718.
  • 10Klinke DJ 2nd. Signal transduction networks in cancer: quantitative parameters influence network topology[J]. Cancer Res, 2010,70(5): 1773-1782.

引证文献4

二级引证文献14

现代医药卫生
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部